Replacing prednisolone with dexamethasone to overcome the resistance to abiraterone in castration-resistant prostate cancer: a clinical case
https://doi.org/10.17650/1726-9776-2020-16-2-162-168
Abstract
Nowadays there are several effective drugs to treat castration-resistant prostate cancer. However, treatment options are still limited. In this regard, overcoming the resistance to the prescribed treatment remains extremely important. One possible way is to replace prednisone with dexamethasone when using abiraterone acetate. There are several studies, including randomized ones, which confirm the rationality of this method. We present a literature review and our own clinical observation, which demonstrates the possibility of repeated long-term (3 years) use of abiraterone acetate after replacing a steroid drug in an intensively pre-treated patient with castration-resistant prostate cancer.
About the Authors
A. A. Meshcheryakov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: not
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
Competing Interests: not
O. O. Gordeeva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: not
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
Competing Interests: not
References
1. Malignant tumors in Russia in 2017 (morbidity and mortality). Eds.: А^. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).
2. National Comprehensive Cancer Network (2020). Prostate cancer (version 2.2020).
3. Parker C., Gillessen S., Heidenreich A., Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines. Ann Oncol 2015;26(suppl 5):v69-77. DOI: 10.1093/annonc/mdv222.
4. Nosov D.A., Volkova M.I., Gladkov O.A. et al. Practical recommendations for prostate cancer treatment. Malignant tumors: RUSSCO practical guidelines, 2019 (Vol. 9). Pp. 519-532. (In Russ.).
5. Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983—92. DOI: 10.1016/S1470-2045(12)70379-0.
6. Miller K., Carles J., Gschwend J.E. et al. The Phase 3 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and Gleason score. Eur Urol 2018;74(1):17-23. DOI: 10.1016/j.eururo.2017.08.035.
7. Venkitaraman R., Thomas K., Huddart R.A. et al. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 2008;101(4):440-3. DOI: 10.1111/j.1464-410X.2007.07261.x.
8. Venkitaraman R., Lorente D., Murthy V. et al. A randomized phase 2 trial of dexamethasone versus prednisolone in castration resistant prostate cancer. Eur Urol 2015;67(4):673—9. DOI: 10.1016/j.eururo.2014.10.004.
9. Lorente D., Omlin A., Ferraldeschi R. et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 2014;111(12):2248-53. DOI: 10.1038/bjc.2014.531.
10. Romero-Laorden N., Lozano R., Jayaram A. et al. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer 2018;119(9):1052-9. DOI: 10.1038/s41416-018-0123-9.
11. Roviello G., Petrioli R., Bonetta A. et al. Corticosteroid switch in heavily pretreated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. Invest New Drugs 2018;36(6):1110— 5. DOI: 10.1007/s10637-018-0685-7.
12. Fenioux C., Louvet C., Charton E. et al. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU Int 2019;123(2):300-6. DOI: 10.1111/bju.14511.
13. Zanardi E., Soldato D., Latocca M.M. et al. To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone. Ther Adv Urol 2019;11:1-5. DOI: 10.1177/1756287219854908.
14. Roviello G., Sobhani N., Corona S.P., D’Angelo A. Corticosteroid switch after progression on abiraterone acetate plus prednisone. Int J Clin Oncol 2020;25(2):240-6. DOI: 10.1007/s10147-019-01577-w.
Review
For citations:
Meshcheryakov A.A., Gordeeva O.O. Replacing prednisolone with dexamethasone to overcome the resistance to abiraterone in castration-resistant prostate cancer: a clinical case. Cancer Urology. 2020;16(2):162-168. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-2-162-168
Views:
6980
Email this article 